- Home
- BIIB vs DXCM Comparison
BIIB vs DXCM Comparison
Compare BIIB & DXCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- DXCM
- Stock Information
- Founded
- BIIB 1978
- DXCM 1999
- Country
- BIIB United States
- DXCM United States
- Employees
- BIIB N/A
- DXCM N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- DXCM Medical/Dental Instruments
- Sector
- BIIB Health Care
- DXCM Health Care
- Exchange
- BIIB Nasdaq
- DXCM Nasdaq
- Market Cap
- BIIB 25.1B
- DXCM 28.0B
- IPO Year
- BIIB 1991
- DXCM 2005
- Fundamental
- Price
- BIIB $149.02
- DXCM $80.24
- Analyst Decision
- BIIB Buy
- DXCM Buy
- Analyst Count
- BIIB 26
- DXCM 17
- Target Price
- BIIB $248.00
- DXCM $98.00
- AVG Volume (30 Days)
- BIIB 1.6M
- DXCM 3.4M
- Earning Date
- BIIB 02-11-2025
- DXCM 02-06-2025
- Dividend Yield
- BIIB N/A
- DXCM N/A
- EPS Growth
- BIIB 10.05
- DXCM 83.21
- EPS
- BIIB 11.06
- DXCM 1.67
- Revenue
- BIIB $9,607,500,000.00
- DXCM $3,954,000,000.00
- Revenue This Year
- BIIB N/A
- DXCM $13.10
- Revenue Next Year
- BIIB N/A
- DXCM $14.74
- P/E Ratio
- BIIB $13.47
- DXCM $48.12
- Revenue Growth
- BIIB N/A
- DXCM 16.19
- 52 Week Low
- BIIB $145.07
- DXCM $62.34
- 52 Week High
- BIIB $268.30
- DXCM $142.00
- Technical
- Relative Strength Index (RSI)
- BIIB 32.44
- DXCM 58.78
- Support Level
- BIIB $145.07
- DXCM $74.50
- Resistance Level
- BIIB $149.92
- DXCM $81.51
- Average True Range (ATR)
- BIIB 3.81
- DXCM 2.57
- MACD
- BIIB 0.05
- DXCM -0.10
- Stochastic Oscillator
- BIIB 22.51
- DXCM 81.88
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About DXCM DexCom Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.